Reply to vorinostat induced bone loss in mice

摘要

Dear Editor, Thank you for the opportunity to respond to Xu et al.'s letter regarding our study published in Bone in 2011 [1]. In that study we tested the effects of vorinostat (SAHA, Zolinza?) on bone mass in wildtype C57B1/6J mice and on the in vitro mineralization of murine bone marrow-derived stromal cell (BMSC) cultures. We found that vorinostat negatively impacts cell cycle progression and mineralization of BMSC cultures and causes bone loss in vivo. Xu et al. contend that this vorinostat dose and/or delivery regimen induced "general toxicity". Their interpretation is based on daily body weights reported in our manuscript. Xu et al. do not explain what they mean by "general toxicity in the mice"; but the lack of weight loss and the rapid weight gain after suspension of the treatment suggests that there was no long-term damage to vital organ systems. We do not know why mice being treated with vorinostat did not gain weight during treatment as mice in the control group did. One testable hypothesis is that treated mice reduced their food consumption, a complication observed in rats receiving vorinostat [2].